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The rheumatic diseases have been associated with accelerated atherosclerosis. Rheumatoid arthritis (RA)
is a systemic inﬂammatory disease characterized by persistent synovial inﬂammation which leads to
disability and structural changes in joints. Epidemiological studies have demonstrated an increased
cardiovascular mortality in patients with RA. In these patients, atherosclerotic plaque occurs earlier, and
it has a faster evolution than in general population. Atherosclerosis (AT) is also an inﬂammatory disease
partly mediated by cytokines, many of them involved on chronic synovitis. Our group has developed
a rabbit experimental model of AT aggravated by chronic arthritis to study inﬂammatory mechanisms
involved on the progression of vascular lesions and their response to drugs. A preliminary study using
this model suggests a beneﬁcial effect of chondroitin sulphate (CS), a drug recommended for the
treatment of osteoarthritis, in controlling AT lesions. Yet clinical trials should be conducted with this
compound to address the same hypothesis in human studies.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Atherosclerosis and rheumatic diseases
The vascular endothelium is involved in the pathogenesis of
inﬂammatory rheumatic diseases. Rheumatoid arthritis (RA),
systemic lupus erythematosus, systemic sclerosis and the anti-
phospholipid syndrome have been associated with accelerated
atherosclerosis. In this section, we will take RA as a prototype of
these rheumatic diseases. RA is a chronic systemic inﬂammatory
disease that primarily affects the joints, and it is marked by
inﬂammatory changes in the synovial membranes and articular
structures. RA is the most common chronic inﬂammatory condi-
tion, affecting approximately 1% of the adult population in devel-
oped populations1. In addition to their negative impact on quality of
life, epidemiological studies have also consistently demonstrated
an increasedmortality in patients with RA, regardless of steroid use
and the presence of rheumatoid factor, when compared with
general population2,3. The major underlying cause for this excess
mortality in RA seems to be the cardiovascular events subsequent
to premature atherosclerosis. Cardiovascular mortality in RA is
more frequent, regardless of RA manifestations, than would be
expected from the proﬁle of traditional cardiovascular risk factors
(age, gender, diabetes mellitus, hypercholesterolaemia, hyperten-
sion, smoking status, sedentary lifestyle and family history of earlyo: Raquel Largo and Gabriel
ory, Fundación Jimenez Diaz,
04978; Fax: 34-915442636.
s Research Society International. Pcoronary artery disease), especially in the youngest population
where little or no atherosclerosis would be expected4. Several
studies have demonstrated an increased prevalence of atheroscle-
rotic plaque in patients with RA relative to controls5,6 and that the
atherogenic process is accelerated after the onset of RA7. Moreover,
RA activity has been recently associated with carotid plaque
instability and RA has been proposed as a novel cardiovascular risk
factor with severity comparable to that of diabetes mellitus8.
Atherosclerosis was formerly considered a passive disease of lipid
deposition in arteries with formation of plaques that results in tissue
ischaemia and thrombus, however, during the last decade it has
become increasingly acknowledged that atherosclerosis is also
a chronic inﬂammatory process. Atherosclerosis is inﬂuenced by
rheumatoid factor9, and mediators of synovitis (TNF-a, IL-6, IL-1)
through their effect promoting macrophages, B and T lymphocytes,
smooth muscle cells and endothelial cells activation, expression of
surfaceadhesionmoleculesas themonocyte chemoattractantprotein
1, andmigration of leukocyte to the subendothelial layers. Here, these
activated cells, in conjunctionwithoxidized low-density lipoproteins,
integrate into the fattystreaksprecursorsof atheroscleroticplaques10,
insulin resistance11, dyslipidemia12 ﬁbrinolysis13 and circulating C-
reactive protein (CRP) levels14. Thus, cardiovascular disease has been
considered an extra-articular manifestation of RA15.Atherosclerosis and osteoarthritis (OA)
OA is the most prevalent joint disorder in ageing population of
the developed world. OA is a disease affecting all joint tissues,ublished by Elsevier Ltd. All rights reserved.
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the most marked changes. Established risk factors for OA are age,
female gender, and obesity16. The association between obesity and
OA is still not fully understood. Indeed, the obesity-related
mechanical stress may explain this association for hip or knee OA,
but it does not explain the reported association between obesity
and hand OA. This leads one to think that other alterations related
to obesity might be linked with OA. Obesity and OA are indepen-
dent factors associated with atherosclerosis17,18 and it has been
postulated that a reduced blood supply to subchondral bone might
underlie the development of OA19. The articular cartilage is an
avascular tissue that receives more than 50% of nutrients and
oxygen from the subchondral vessels20. In this context, the sug-
gested consequences of bone ischaemia and endothelial dysfunc-
tion are: (1) reduction of the nutrients and oxygen supply to
overlying cartilage causing catabolic and reparative processes in
the cartilage; (2) osteocytes death and increased turnover of the
subchondral bone19; (3) induction of bone marrow oedema21,
a potent risk factor for structural deterioration in knee OA22,23; (4)
inﬁltration of leukocytes into the surrounding structures and
initiation of inﬂammatory responses from these tissues24. All these
alterations may compromise the shock absorption capacity of the
subchondral bone leading to cartilage damage. Epidemiological
studies reveal that the risk factors for progression are not the same
as those for initiation25. Whether atherosclerosis participates in OA
initiation or progression needs to be elucidated.Animal models of atherosclerosis
Atherosclerosis is a polygenic and environmental-dependent
disease. The inability to study atherosclerosis in a controlled
manner in humans forces us to use animal models for studying
atherosclerosis in depth. Experimental genetic murine models of
atherosclerosis were developed in the late 1990s26, but currently
we know that the suitable specie in which to study atherosclerosis
is the rabbit because it has a lipid metabolism similar to the human,
and it is an animal susceptible to diet-induced atherosclerosis. In
the literature we can ﬁnd experimental murine models of accel-
erated atherosclerosis by systemic inﬂammation in which the
inﬂammation is generated inducing hyperlipidemia27, lupus28,
diet-induced obesity29 or diabetes30. Recently, our group has
developed an experimental model in rabbits to reproduce the
setting of systemic inﬂammation associated with RA in order to
study inﬂammation-related mechanisms of vascular lesions31.
Studies were conducted on male New Zealand rabbits and the
induction of chronic antigen-induced arthritis and atherosclerosis
was synchronized as outlined in Fig. 1. To initiate atherosclerosis,
animals were fed with a hyperlipidaemic diet enriched with 2%
cholesterol and 6% peanut oil along all the study. Two weeks after
the administration of this diet, an endothelial lesionwas induced in
both femoral arteries by infusion of gaseous nitrogen inside the
femoral arteries. To induce antigen-arthritis, animals were givenFig. 1. Schematic representation of the experimental model.two intradermal injections of 1 ml ovalbumin in Freud’s complete
adjuvant. Five days after the last injection, 1 ml of ovalbumin was
also injected into the knee joints on a weekly basis over the
following 4 weeks. The control groups were induced to have either
AIA alone or AT alone. Brieﬂy, with that study we demonstrated
that rabbits with combined atherosclerosis and chronic antigen-
induced arthritis showed more pronounced systemic (higher
serum CRP and IL-6 levels) and synovial inﬂammation, a higher
activation of circulating mononuclear cells, and more secondary
atherosclerotic lesions in the aorta than those animals with the
single phenotype. Moreover, our results indicated that the presence
of chronic arthritis in hyperlipemic rabbit results in a more
vulnerable vessel wall at the site of the endothelial characterized
for an increased expression of the pro-inﬂammatory molecules
COX-2 and CCL-2. In summary, we characterized an experimental
model that represents a new approach to the study of secondary
atherosclerosis, and showed that chronic arthritis is a risk factor for
the development of atherosclerotic lesions.
Treatment with chondroitin sulphate (CS)
CS is a natural glycosaminoglycan predominantly found in the
extra-cellular matrix surrounding cartilage, ligaments, tendons,
blood vessels and skin32,33. CS belongs to the oral symptomatic
slow-acting drugs and was included in the EULAR recommenda-
tions for the treatment of knee OA in 2003. It has been reported that
CS reduces pain and swelling, improves articular function and
prevents joint space narrowing34. Its therapeutic effect is probably
the result of its anti-inﬂammatory activity in chondrocytes and
synovial cells. In this sense, it has been demonstrated that CS
decreases NF-kB nuclear translocation and consequently, the
synthesis of several pro-inﬂammatory mediators (COX-2, NOSe, IL-
1b, TNF-a, etc.)35. There is preliminary evidence suggesting that CS
may also improve other inﬂammatory disorders such as athero-
sclerosis36. Accordingly, our group developed a study to examine
the anti-inﬂammatory properties of CS on atherosclerotic lesions in
the rabbit model of induced atherosclerosis above described37. In
that study, 1 week after the ﬁrst ovalbumin injection, rabbits were
randomly allocated into two groups; one group received daily
100 mg/kg of CS and the other was given no treatment and was
used as a control group. The results derived from that study
demonstrated that, in rabbits, treatment with CS produces a clear
reduction of systemic inﬂammation (serum CRP and IL-6 levels;
Table I) and of pro-inﬂammatory activation of the circulating
mononuclear cells, and an improvement in the inﬂammatory
response of atherosclerotic lesions in femoral re-stenosis, as well as
a decrease in the number of aortic atherosclerotic lesions.
Regarding the molecular mechanisms underlying these anti-
inﬂammatory effects, results from different studies31,35,37e39,
showed that CS and other glycosaminoglycans with similar struc-
tures such as glucosamine sulphate reduce NF-kB activation and
consequently COX-2 and nitric oxide synthesis and PGE2 release in
circulating mononuclear cells, chondrocytes, ﬁbroblasts and
macrophages. On the other hand, in our experimental model, CS
reduced the intima/media thickness ratio in the arteries of injured
rabbits (Fig. 2) and the neointimal macrophage inﬁltration,Table I
Effect of chondroitin sulphate (CS) administration to rabbits with atherosclerosis
plus chronic arthritis on IL-6 and CRP concentration in serum
Healthy (n¼ 15) NT (n¼ 15) CS (n¼ 9)
IL-6 (pg/ml) 162.9 22.2 403.9 28.0* 173.41 58.4#
CRP (mg/ml) 391.5 40 145,586.6 21,852.6* 70,600.4 17,521.2*,#
Data are shown as mean S.E.M.; *P< 0.01 vs healthy controls; #P< 0.05 vs NT
rabbits.
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process linked to vascular injury and it could also interfere with
inﬂammatory cell recruitment to the neointima of the femoral
artery through the inhibition of CCL-2.Fig. 2. Etiopathogenic mechanisms linking erosive, chronic arthritis and atherosclerosis. R
accelerate atherosclerosis by several mechanisms. Both, IL-6 and TNF-a stimulate the CRP, an
inducing impaired ﬁbrinolysis. CRP induces nuclear translocation of NF-kB in circulating m
vessel, stimulating the release and activation of matrix-degrading enzymes (MMP-2, MMP
induce plaque instability and rupture. CS would favours the plaque stability by decreasi
mediators (NO, IL-1, TNF-a, COX-2, etc.) and chemoattractant cytokines. The CS sites of actThe use of CS or glucosamine could be limited by the results of
a recent study showing that the treatment of OA with glucosamine
worsens the insulin resistance, a pro-atherogenic alteration, in
humans40. We have no data of insulin resistance in our rabbits, butheumatoid joints secrete pro-inﬂammatory soluble factors in the blood stream that
d PAI-1 synthesis and secretion by the liver, enhancing the systemic inﬂammation and
ononuclear cells. NF-kB increases the gene expression of both COX-2 and CCL-2 in the
-9), and monocytes inﬁltration and activations. All these NF-kB-related mechanisms
ng NF-kB nuclear translocation and consequently the synthesis of pro-inﬂammatory
uation are marked in red.
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resistance41.
In summary, this preliminary study suggests a beneﬁcial effect
of CS in controlling atherosclerotic lesions in rabbits. Clinical trials
should be conducted with this compound to address the same
hypothesis in human studies.
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